atenolol has been researched along with Arterial Diseases, Carotid in 10 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 9.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 5.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| "The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study was a double-blind trial in patients with hypertension at increased cardiovascular risk with carotid wall thickening and a defined atherosclerotic plaque that used non-invasive 2- and 3-dimensionaL (D) ultrasound (US), to compare the effects of a 2-year treatment based on either olmesartan medoxomil or atenolol on common carotid (CC) intima-media thickness (IMT) and plaque volume (PV)." | 5.12 | Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. ( Agabiti-Rosei, E; Laeis, P; Ludwig, M; Scholze, J; Schremmer, D; Schwandt, P; Stumpe, KO; Zielinski, T, 2007) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind trial in 2334 patients with hypertension that compared the effects of a 4-year treatment based on either lacidipine or atenolol on an index of carotid atherosclerosis, the mean of the maximum intima-media thicknesses (IMT) in far walls of common carotids and bifurcations (CBM(max))." | 5.10 | Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Reid, JL; Rizzini, P; Rodicio, J; Safar, M; Zanchetti, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bombelli, M | 1 |
| Macchiarulo, M | 1 |
| Facchetti, R | 2 |
| Maggiolini, D | 1 |
| Cuspidi, C | 1 |
| Parati, G | 2 |
| Mancia, G | 5 |
| Grassi, G | 1 |
| Stumpe, KO | 1 |
| Agabiti-Rosei, E | 1 |
| Zielinski, T | 1 |
| Schremmer, D | 1 |
| Scholze, J | 1 |
| Laeis, P | 1 |
| Schwandt, P | 1 |
| Ludwig, M | 1 |
| Zanchetti, A | 4 |
| Bond, MG | 3 |
| Hennig, M | 3 |
| Neiss, A | 1 |
| Dal Palù, C | 1 |
| Hansson, L | 1 |
| Magnani, B | 1 |
| Rahn, KH | 1 |
| Reid, JL | 1 |
| Rodicio, J | 1 |
| Safar, M | 1 |
| Eckes, L | 2 |
| Rizzini, P | 1 |
| Liebson, PR | 1 |
| Tang, R | 2 |
| Hollweck, R | 1 |
| Micheli, D | 1 |
| Paliotti, R | 1 |
| Ciulla, MM | 1 |
| Magrini, F | 1 |
| Fomin, VV | 1 |
| Moiseev, SV | 1 |
| Fossum, E | 1 |
| Olsen, MH | 1 |
| Høieggen, A | 1 |
| Wachtell, K | 1 |
| Reims, HM | 1 |
| Kjeldsen, SE | 1 |
| Ibsen, H | 1 |
| Wan, Y | 1 |
| Julius, S | 1 |
| Leonetti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for atenolol and Arterial Diseases, Carotid
| Article | Year |
|---|---|
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2005 |
9 trials available for atenolol and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis.
Topics: Antihypertensive Agents; Atenolol; Atherosclerosis; Blood Pressure; Carotid Artery Diseases; Dihydro | 2019 |
Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Carotid | 2007 |
Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis.
Topics: Adrenergic Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blo | 2012 |
Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2002 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Disease | 2003 |
Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Aged; Antihypertensive Agents; Atenolol; Carotid Artery Diseases; Carotid Artery, Common; Carotid Ar | 2004 |
Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Carotid Arteries; Carotid Artery Diseases; Dihydropy | 2005 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
[The preliminary clinical evidence from the ELSA study. The European Lacidipine Study on Atherosclerosis].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Carotid Artery | 1995 |